No Data
BeiGene Gains FDA Nod for TEVIMBRA, Marking Key Progress in Oncology Treatments
Asia-Pacific Markets Flat in Thin Holiday Trading, PBoC Holds MLF Rate Steady for Third Month
PBoC Holds MLF Rate Steady for Third Month, Withdraws Largest Cash Since 2014
Selling ATU's USA and United Kingdom Business, the strategy behind WUXI APPTEC.
There is gain in loss.
WUXI APPTEC will transfer the WuXi ATU Business to a USA Fund. Is the "optimal solution" for the "gray rhino" of the Biological Safety Act?
① This evening, WUXI APPTEC announced that it will transfer its WuXi ATU Business in the USA and United Kingdom to the USA Private Equity Fund Altaris in exchange for Cash.; ② In the first three quarters, WuXi ATU achieved revenue of 0.853 billion, accounting for only about 3% of the total revenue for the first three quarters.; ③ After the transfer of this Business, the accusations and suspicions related to its gene business may be cleared under the Biosecurity Act.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.